Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study

Clinical Cardiology
Deepak L BhattTHEMIS Steering Committee

Abstract

In the setting of prior myocardial infarction, the oral antiplatelet ticagrelor added to aspirin reduced the risk of recurrent ischemic events, especially, in those with diabetes mellitus. Patients with stable coronary disease and diabetes are also at elevated risk and might benefit from dual antiplatelet therapy. The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS, NCT01991795) is a Phase 3b randomized, double-blinded, placebo-controlled trial of ticagrelor vs placebo, on top of low dose aspirin. Patients ≥50 years with type 2 diabetes receiving anti-diabetic medications for at least 6 months with stable coronary artery disease as determined by a history of previous percutaneous coronary intervention, bypass grafting, or angiographic stenosis of ≥50% of at least one coronary artery were enrolled. Patients with known prior myocardial infarction (MI) or stroke were excluded. The primary efficacy endpoint is a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety endpoint is Thrombolysis in Myocardial Infarction major bleeding. A total of 19 220 patients worldwide have been randomized and at least 1385 adjudicated primary efficacy endpoint events a...Continue Reading

References

Aug 25, 2001·Lancet·S R MehtaUNKNOWN Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
Sep 17, 2002·The American Journal of Cardiology·Deepak L BhattEric J Topol
Mar 15, 2006·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHARISMA Investigators
Jul 18, 2006·Journal of the American College of Cardiology·Dominick J AngiolilloAntonio Fernandez-Ortiz
May 15, 2007·Journal of the American College of Cardiology·Deepak L BhattUNKNOWN CHARISMA Investigators
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Jan 19, 2010·Lancet·Christopher P CannonUNKNOWN PLATelet inhibition and patient Outcomes Investigators
Feb 24, 2011·Circulation·José Luis Ferreiro, Dominick J Angiolillo
Mar 10, 2011·Circulation. Cardiovascular Interventions·Davide CapodannoDominick J Angiolillo
Aug 28, 2012·The New England Journal of Medicine·Matthew T RoeUNKNOWN TRILOGY ACS Investigators
Oct 17, 2012·American Heart Journal·Jean-Guillaume DillingerPatrick Henry
Sep 6, 2014·Journal of the American College of Cardiology·Dominick J AngiolilloTheodore A Bass
Mar 17, 2015·The New England Journal of Medicine·Marc P BonacaUNKNOWN PEGASUS-TIMI 54 Steering Committee and Investigators
Mar 12, 2016·Journal of the American College of Cardiology·Robert F StoreyMarc S Sabatine
Apr 6, 2016·Journal of the American College of Cardiology·Deepak L BhattPh Gabriel Steg
Apr 6, 2016·Journal of the American College of Cardiology·Marc P BonacaMarc S Sabatine
May 11, 2016·The New England Journal of Medicine·S Claiborne JohnstonUNKNOWN SOCRATES Steering Committee and Investigators
Nov 15, 2016·Circulation·W Schuyler JonesUNKNOWN International Steering Committee and Investigators of the EUCLID Trial
Jan 17, 2017·Journal of the American College of Cardiology·Deepak L BhattUpendra Marathi
Aug 28, 2018·The New England Journal of Medicine·UNKNOWN ASCEND Study Collaborative GroupJane Armitage
Sep 18, 2018·The New England Journal of Medicine·John J McNeilUNKNOWN ASPREE Investigator Group

❮ Previous
Next ❯

Citations

Sep 3, 2019·The New England Journal of Medicine·P Gabriel StegUNKNOWN THEMIS Steering Committee and Investigators
Apr 14, 2020·Circulation·Suzanne V ArnoldUNKNOWN American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology
Nov 27, 2020·European Heart Journal Supplements : Journal of the European Society of Cardiology·Laura Gatto, Francesco Prati
May 15, 2021·Journal of the American College of Cardiology·Lawrence A LeiterUNKNOWN THEMIS Steering Committee and Investigators
Nov 25, 2021·Circulation. Cardiovascular Interventions·Jeremie AbtanPh Gabriel Steg

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass

Clinical Trials Mentioned

NCT01991795

Software Mentioned

THEMIS
PEGASUS

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.